BioCentury Innovations Emerging Company Profile "ValoTx: adding tumor antigens to oncolytic viruses"

"With platforms that can rapidly display tumor-specific antigens on oncolytic viruses without genetic engineering, Valo is positioning itself as an attractive collaborator for immunooncology companies..."

Read full article here: https://drive.google.com/file/d/1Ye_k2h4nUh9R5FxxpAlIqiH9ko5_xQtr/view?usp=sharing